A Phase I study of CA-4948 in patients with acute myeloid leukemia and myelodysplastic syndromes, including patients with spliceosome mutations that encode oncogenic IRAK4-L
Latest Information Update: 14 May 2020
Price :
$35 *
At a glance
- Drugs Emavusertib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 12 May 2020 According to a Curis media release, the company expects to initiate this trial in the second quarter of 2020.
- 24 Mar 2020 New trial record
- 19 Mar 2020 According to a Curis media release, the company expects to initiate this trial in the first half of 2020.